Payment overview · 2025
General Payments
$153.54
7 reported records · 3 companies
Healthcare provider profile · identity verified
Prabha Mohan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · KAUFMAN, TX · NPI 1548362098
Verified facts
What the public records show
CMS Open Payments records show Prabha Mohan, M.D. received $153.54 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 70.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $107.69 | 70.1% | 5 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $29.92 | 19.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.93 | 10.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $153.54 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $107.69 | 5 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $29.92 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 509 | 155 |
| Pantoprazole Sodium | Pantoprazole Sodium | 486 | 116 |
| Gabapentin | Gabapentin | 454 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 422 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 421 | 99 |
| Lisinopril | Lisinopril | 379 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 77 |
| Losartan Potassium | Losartan Potassium | 282 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 278 | 81 |
| Metformin Hcl | Metformin Hcl | 270 | 63 |
| Furosemide | Furosemide | 247 | 68 |
| Simvastatin | Simvastatin | 246 | 65 |
| Meloxicam | Meloxicam | 242 | 82 |
| Carvedilol | Carvedilol | 238 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 210 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 49 |
| Trazodone Hcl | Trazodone Hcl | 198 | 47 |
| Omeprazole | Omeprazole | 186 | 49 |
| Sertraline Hcl | Sertraline Hcl | 186 | 47 |
| Ozempic | Semaglutide | 183 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 169 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 39 |
| Buspirone Hcl | Buspirone Hcl | 137 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 35 |
| Potassium Chloride | Potassium Chloride | 120 | 34 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 119 | 36 |
| Eliquis | Apixaban | 113 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 45 |
| Jardiance | Empagliflozin | 103 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 99 | 19 |
| Tramadol Hcl | Tramadol Hcl | 95 | 23 |
| Montelukast Sodium | Montelukast Sodium | 93 | 22 |
| Celecoxib | Celecoxib | 91 | 27 |
| Azithromycin | Azithromycin | 89 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 77 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 77 | 16 |
| Alendronate Sodium | Alendronate Sodium | 73 | 19 |
| Clonidine Hcl | Clonidine Hcl | 73 | 20 |
| Famotidine | Famotidine | 71 | 16 |
| Pregabalin | Pregabalin | 71 | 26 |
| Glimepiride | Glimepiride | 68 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 17 |
| Prednisone | Prednisone | 67 | 62 |
| Eszopiclone | Eszopiclone | 64 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 11 |
| Ibuprofen | Ibuprofen | 60 | 15 |
| Baclofen | Baclofen | 58 | 12 |
| Allopurinol | Allopurinol | 55 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 11 |
| Lorazepam | Lorazepam | 55 | 29 |
| Bupropion Hcl | Bupropion Hcl | 54 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 16 |
| Topiramate | Topiramate | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 32 |
| Mirtazapine | Mirtazapine | 47 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 12 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 39 | 35 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 32 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 21 |
| Atenolol | Atenolol | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 22 |
| Estradiol | Estradiol | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 13 |
| Valsartan | Valsartan | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 16 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 12 |
| Amoxicillin | Amoxicillin | 22 | 21 |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Etodolac | Etodolac | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $153.54 · 7 records | ABBVIE INC. | EVENITY, JOURNAVX, PROLIA, VRAYLAR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error